US 11,052,149 B2
Methods and compositions for inducing an immune response
Jenny P.-Y. Ting, Chapel Hill, NC (US); Robert Junkins, Durham, NC (US); Brandon Johnson, Durham, NC (US); Kristy Ainslie, Chapel Hill, NC (US); Eric Bachelder, Chapel Hill, NC (US); Matthew Gallovic, Carrboro, NC (US); Michael Collier, Durham, NC (US); and Ning Cheng, Cary, NC (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Appl. No. 16/334,153
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
PCT Filed Sep. 19, 2017, PCT No. PCT/US2017/052270
§ 371(c)(1), (2) Date Mar. 18, 2019,
PCT Pub. No. WO2018/053508, PCT Pub. Date Mar. 22, 2018.
Claims priority of provisional application 62/396,774, filed on Sep. 19, 2016.
Prior Publication US 2019/0275144 A1, Sep. 12, 2019
Int. Cl. A61K 39/39 (2006.01); A61K 39/145 (2006.01); A61P 31/16 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 31/7084 (2006.01); A61K 39/12 (2006.01); A61K 9/127 (2006.01); A61K 31/4745 (2006.01); A61K 9/16 (2006.01); A61P 25/28 (2006.01); A61K 9/00 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1272 (2013.01); A61K 9/1647 (2013.01); A61K 31/4745 (2013.01); A61K 31/7084 (2013.01); A61K 39/0008 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61P 25/28 (2018.01); A61P 31/16 (2018.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); Y02A 50/30 (2018.01)] 2 Claims
 
1. A method of ameliorating, alleviating, decreasing symptom(s), or delaying progression of an infectious disease, cancer, or an autoimmune disorder that requires activation of the stimulator of interferon genes (STING) pathway, comprising administering to a subject in need thereof an effective amount of a composition comprising:
a) acetalated dextran;
b) an agonist of the stimulator of interferon genes (STING) receptor and/or a different immunostimulatory agent; and
c) optionally, an antigen,
wherein the composition is formulated in electrosprayed microparticles.